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Emerging evidence shows a broad spectrum of biological functions of tissue factor (TF). TF classical role in initiating
the extrinsic blood coagulation and its direct thrombotic action in close relation to cardiovascular risks have long been
established. TF overexpression/hypercoagulability often observed in many clinical conditions certainly expands its role
in proinﬂammation, diabetes, obesity, cardiovascular diseases, angiogenesis, tumor metastasis, wound repairs, embryonic
development, cell adhesion/migration, innate immunity, infection, pregnancy loss, and many others. This paper broadly covers
seminal observations to discuss TF pathogenic roles in relation to diverse disease development or manifestation. Biochemically,
extracellular TF signaling interfaced through protease-activated receptors (PARs) elicits cellular activation and inﬂammatory
responses. TF diverse biological roles are associated with either coagulation-dependent or noncoagulation-mediated actions.
Apparently, TF hypercoagulability refuels a coagulation-inﬂammation-thrombosis circuit in “autocrine” or “paracrine” fashions,
which triggers a wide spectrum of pathophysiology. Accordingly, TF suppression, anticoagulation, PAR blockade, or general anti-
inﬂammation oﬀers an array of therapeutical beneﬁts for easing diverse pathological conditions.
1. Introduction:TissueFactor Biology
Tissue factor (TF), also known as factor III, essentially
provides additional protection to vital organs prone to
mechanical injury; its strategic location is considered as a
hemostatic envelope for arresting bleeding from vascular
beds. High TF expression is found in highly vascularized
organs (cells) such as the brain (e.g., astrocytes), placenta
(e.g., trophoblasts), and the lungs (e.g., alveolar cells)
followed by the heart (e.g., cardiac myocytes, pericytes,
ﬁbroblasts), kidney, intestine, testes, and uterus (e.g., epithe-
lial cells surrounding the organs). The low expression is
detected in the spleen, thymus, and liver [1]. Circulating
(blood-borne) TF is mainly derived from its expression in
bloodcells(e.g.,monocytes,macrophages,granulocytes,and
platelets), platelet-free microparticles containing TF shed
from cells, or even soluble TF protein; the serum level can
be easily measured by TF antigen, ELISA, TF procoagulant
activity (PCA), and so forth (for review, see [2]).
Full-lengthTF(Figure 1),amembraneintegralglycopro-
tein (46kDa), is a 263-amino acid single-chain polypeptide
classiﬁed as CD142 (Type II cytokine receptor) with a 219-
amino-acid extracellular N-terminus and a 23-amino-acid
transmembrane domain followed by an intracellular 21-
amino-acid C-terminus [3, 4]. The extracellular region
contains FVII/VIIa binding domains. Extracellular soluble
form (sTF) could be released from EC [5]i nr e s p o n s et o
proinﬂammatory cytokines. The intracellular domain could
undergo serine phosphorylation(s), which could modify
its function [6–8]; for instance, the cytoplasmic domain
negatively regulates TF expression, which is mediated by
suppressed Erk1/2 phosphorylation.
TF initiates the extrinsic coagulation that plays an inte-
gral role in blood coagulation, thrombin (FIIa) generation,
and thrombi formation in close relation to thrombosis
and cardiovascular dysfunctions [9, 10]. Such extracellular
TF signaling proceeds with the sequential generation of
coagulant mediators (FVIIa, FXa, and FIIa: active serine
proteases) and ﬁbrin production, all of which are proin-
ﬂammatory [4]. TF extends its roles to diverse biolog-
ical phenomena related to either ro both of these two
major thrombotic and inﬂammatory events. Emerging evi-
dence shows TF involvement in wound repairs, embryonic
development, angiogenesis, tumor metastasis, cell adhe-
sion/migration, innate immunity, and many pathological
conditions.2 International Journal of Inﬂammation
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Figure 1: TF structure. The 46-kDa membrane-bound single
polypeptide chain consists of extracellular, transmembrane, and
cytoplasmic domains. There are 2 intrachain disulﬁde bridges
(Cys49-Cys57andCys186-Cys209,showninblue)intheextracellu-
lar domain where it also contains FVII/FVIIa binding domain (see
text) initiating signaling cascade for the extrinsic blood coagulation
(Figure 2, left panel). There are three serine residues (shown in
red) in the cytoplasmic domain for undergoing phosphorylation.
∗Denotes 3 proposed glycosylation sites at Asn11, 124, and 137.
Adopted and modiﬁed from [3].
2. Regulation of Tissue Factor Expression
TF usually in its latent (cryptic) form is often upregulated
(decrypted) upon vascular injury (by protein disulﬁde
isomerase with phosphatidylserine (PS) exposure) [10–12],
inﬂammation (e.g., LPS, ILs, TNF-α,C - r e a c t i v ep r o t e i n
(CRP), C. pneumoniae), IFN, MCP-1, ICAM, P-selectin,
CD40/40L, PDGF, OxLDL, Lp(a), angiotensin II, plasmin,
complement anaphylatoxin C5a, antiphospholipid antibody
(aPL), advanced glycation endproducts (AGEs), hypoxia,
and so forth (for review, see [4]) in cultures. Enhanced TF
expression has also been reported due to SirT1 inhibition
[13], homocysteine [14], oral contraceptives [15], shear
stress [16], amyloid protein A [17], histamine [18], smoking
[19], nicotine [20], estrogen [21], asbestos [22], serotonin
[23], dexamethasone [24], arachidonic acid (AA) [25], bFGF
[26], VEGF [27], EGF [28], aggregated LDL [29], leptin
[30], urokinase [31], shingosine-1-phosphate [32], or many
others.Ingeneral,TFexpressionismediatedbyactivationsof
intracellular signaling kinases (e.g., PKC, MAPK (Erk, p38))
andothersignalingcomponentssuchastranscriptionfactors
(e.g., AP-1, NFκB, Erg-1) (for review, see [4]). Exposure
to calcium ionophores such as A23187 drastically sustains
cellular TF PCA without increased TF expression in cultures,
which could either have or not have any pathological
implications, and the mechanism of action remains unclear
[4].
Incontrast,itsdownregulationhasbeenreportedinclud-
ing by HMG-CoA reductase inhibitors [33, 34], cyclooxy-
genase (COX) inhibitors [35–37], paclitaxel [38], lysophos-
phatidylcholine [39], insulin [40], nicotinamide [41], nitric
oxide (NO)/or soluble guanylate cyclase activator [42], hy-
droxyurea [43] ,e t h y lp y r u v a t e[ 44], dimethyl sulfoxide
(DMSO) [45], angiotensin converting enzyme (ACE) inhib-
itors [46], adiponectin [47], retinoic acid [48], all-trans
retinoic acid [49], vitamin D3 [50], PGJ2 [51], PPARα ago-
nists (fenoﬁbric acid, WY14643, and GW2331) [52]/activa-
tors (WY14643 and eicosatetraenoic acid) [53], liver X
receptoragonists[54],pentroxifylline[55],phenolics/resver-
atrol derivatives [56], indobufen [57], amiodarone [58],
metformin [59], elevated intracellular cAMP [4], and PI3K/
Akt/PKB signaling [60]. On the molecular biology front,
miR-19[61],shorthairpinRNA[62],hairpinribozyme[63],
or antisense ODN [64–66] readily downregulates TF mRNA
translation and expression.
3.TF-InitiatedExtrinsicCoagulation
In a classical view, TF initiates the extrinsic blood coag-
ulation, which proceeds as Ca+2-dependent extracellular
signaling to sequentially activate zymogens: FVII, factor
X (FX), and prothrombin (FII) for the generation of
coagulant mediators (active serine proteases): FVIIa, FXa,
and thrombin (FIIa), respectively. As a result, FIIa cleaves
oﬀ ﬁbrinogen (FBG) into ﬁbrin monomers that cross-link
to produce insoluble blood clots. The extrinsic pathway
plays an integral role in blood coagulation complemented
by the intrinsic pathway that ensures FIIa regeneration and
clot production (Figure 2,l e f tp a n e l )( f o rr e v i e w ,s e e[ 3, 4,
10, 67]). The intrinsic pathway merging with TF-initiated
extrinsic coagulation at FX activation is beyond the focus of
this paper.
3.1. FVII Activation. FVII readily undergoes proteolytic
activation of peptide bond cleavage between Arg 152 and Ilu
153 by either TF dependence or other serine proteases (e.g.,
FXa, FIXa, FXIa, FXIIa, FIIa, or plasmin), resulting in two
smaller chains of FVIIa. The N-terminus-derived light chain
(∼20KDa) contains the membrane-binding Gla domain,
while the C-terminus-derived heavy chain (∼30 KDa) con-
tains the catalytic domain.
3.2. TF-Dependent FVII Activation. The ability of FVII
to bind its cofactor (TF) has been reported with a-1:2
stoichiometric ratio. It has long been established that Ca+2
and membrane anionic phospholipids are required for TF-
dependent FVII activation. Gla, EGF-1, EGF-2, and protease
domain (PD) in FVII make essential contributions to the
optimal interaction/binding with its counterpart: extracel-
lular sTF1-219. It is said that zymogen FVII aﬃnity for
sTF causes secondary conformational changes of the PD,
dictating the protease activity. EPR study shows multipleInternational Journal of Inﬂammation 3
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IL-1, -6, -8, and -10; TNF-α; TGF-β; PDGF;
bFGF; GM-CSF; ICAM-1; VCAM-1;
VEGF; PAF; P-selectin; E-selectin; MCP-1;
PGE2; c-fos; NF-κB activation, and so forth
IL-1; IL-6; IL-8; ICAM-1; NF-κB activation,
and so forth
Figure 2: TF hypercoagulability and inﬂammation. TF-initiated extrinsic coagulation (left panel) essentially proceeds as extracellular
signalingandresultsinthegenerationofactiveserineprotease(coagulantmediators:FVIIa,FXa,andFIIa)derivedfromtheircorresponding
zymogen activations. FBG is cleaved by FIIa to produce ﬁbrin that is polymerized and cross-linked to yield insoluble blood clots. Such
TF extracellular signaling activates cells for proinﬂammation. Through cell receptors on plasma membrane, signals from the coagulant
mediators (FVIIa, FXa, and FIIa) as well as ﬁbrin mediate diverse intracellular activation and the production of proinﬂammatory mediators
(right panel) including cytokines, adhesion molecules, and growth factors, PAR: protease activated receptor; TLR: Toll-like receptor; IL:
interleukin; NFκB: nuclear factor kappa B.
contacts between two proteins; the Gla binds sTF158 and
207, the EGF-1 binds sTF22 and 140, and the PD binds
sTF45 and 94. In contrast, Gla-domainless-FVII shows a
rapid loss in FVII binding aﬃnity for TF. FVII aﬃnity
is also altered upon modiﬁcation/conformational changes
involving the EGF-1 region. Accordingly, any FVII global
conformationalmisfolding/unfoldingdisruptingthebinding
sites could result in impaired FVII activation.
Furthermore, there are high-aﬃnity Ca+2 binding sites
in Gla, EGF-1, and PD. It has been reported that one Ca+2
molecule binds to PD, another Ca+2 binds to the EGF-
1 domain at a high-aﬃnity site, and seven more Ca+2
molecules bind with variable aﬃnity for the Gla domain.
Thus, it seems likely that Ca+2 could play a critical role
in FVII binding to TF. In addition to PS being essential
for TF-dependent FVII activation, cholesterol enrichment
of primary human monocyte-derived macrophages also
drastically increases TF PCA [68].
3.3. Downstream Sequential Activations. The catalytic func-
tion of the binary complex TF/FVIIa relying in mutual
binding conformation is believed to be directly responsible
for FX and FIX activation. FXa acts as a molecular switch not
only receiving the upstream (extrinsic and intrinsic) signals
but also dictating the downstream coagulation. Strategically,
FXa is an active enzyme component coupled with FVa
in prothrombinase complex located at the center of the
blood coagulation cascade, which converges the clotting
signals derived from both the extrinsic (FVII activation)
and intrinsic (FIX activation) pathways. FXa also undertakes
a feedback activation of FVII. Finally, FIIa derived from
FII cleavage by FXa assumes the main coagulant function
at the termination stage; it directly catalyzes FBG cleavage
releasing ﬁbrinopeptides for ﬁbrin clot production upon
cross-linking. In addition, FIIa activates FXIII, FXI, FVIII, or
FV, assuring the propagation of blood coagulation.
4.TF HypercoagulabilityLeading
to Thrombosis
As a consequence of TF hypercoagulation, thrombo-
sis featuring ﬁbrin overproduction is a direct outcome4 International Journal of Inﬂammation
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Figure 3: Coagulation-inﬂammation-thrombosis circuit. TF hypercoagulability results in direct thrombotic actions (1). TF also plays
converging and diverging roles in driving the coagulation-inﬂammation cycle ((2) coagulation-dependent inﬂammation and (3)
inﬂammation-dependent coagulation). Namely, TF hypercoagulability could result in enormous inﬂammation as the result of continuously
refueling the cycle in which coagulation and inﬂammation promote each other upon the cycle gaining its initial momentum. Thrombosis-
inﬂammation connection (4) is incorporated into the coagulation-inﬂammation cycle to form a complete coagulation-inﬂammation-
thrombosis circuit, which manifests diverse pathological conditions in relation to inﬂammation and thrombosis, including cancers, APS,
cardiovascular dysfunctions, diabetes, obesity, and DIC.
(Figure 3(1)) in addition to proinﬂammatory environment
for thrombogenesis (i.e., inﬂammation-dependent throm-
bosis discussed in Section 7.1). Moreover, elevated FIIa
generation upon hypercoagulation impacts thrombogenesis
by severalfold relevance to platelet activation/aggregation,
clot stabilization, and antiﬁbrinolysis (for review, see [69,
70]).
FIIa activates platelets mainly through protease-activated
receptor (PAR) and glycoproteins (GPs) IIb/IIIa, and GPIb.
PAR-1 is a primary receptor for FIIa by which platelets are
activated to aggregate [71]. Platelet aggregation constitutes
thrombus formation involving cross-linking of adjacent
platelets mediated by the interaction of activated GP IIb/IIIa
with distinct amino acid sequences, LGGAKQAGDV, and/or
RGD, at each end of dimeric FBG molecules [72]. Alter-
natively, FIIa-induced platelet activation could result from
polymerizing ﬁbrin, which involves the recognition sites in
the cross-linking of polymerizing ﬁbrin and surfaceintegrins
via GP Ib. In fact, GP Ib acts as an FIIa-binding site and
promotes platelet activation by low FIIa concentrations [73].
In addition, FIIa activates FXIII, and FXIIIa facilitates the
stabilization and cross-linking of ﬁbrin clots.
Concerning hemostatic imbalance with suppressed ﬁbri-
nolysis, FIIa activates plasma carboxypeptidases recognized
as thrombin activatable ﬁbrinolytic inhibitor (TAFI) that
attenuates ﬁbrinolysis [74] thereby in favor of ﬁbrin depo-
sition/accumulation. Subsequently, TAFI inhibits various
forms of plasminogen activator- (PA-) mediated ﬁbrinolysis
[75]. Upregulated plasminogen activator inhibitor-1 (PAI-
1) expression by FIIa via a PKC-dependent mechanism [76]
couldfurthercontributetoantiﬁbrinolyticprocessandﬁbrin
accumulation.
5. Coagulation-Dependent Inﬂammation
Several lines of evidence reveal in vivo coagulation-
dependent inﬂammation. PARs generally mediate inﬂam-
mation derived from coagulant mediators (e.g., FVIIa, FXa,
and FIIa) and ﬁbrin (Figure 2; right panel). Moreover,
deﬁciencies in natural anticoagulants (e.g., tissue factorInternational Journal of Inﬂammation 5
pathway inhibitor (TFPI), antithrombin (AT III), and acti-
vated protein C (APC)) are often susceptible to sepsis [77],
disseminated intravascular coagulation (DIC) consequences
[78], and inﬂammation [79]. Consistent with such notion of
coagulation-dependent inﬂammation, anticoagulation read-
ily results in anti-inﬂammatory eﬀects in vivo and in vitro
(discussed in Section 10).
5.1. Coagulant Mediators Are Proinﬂammatory
5.1.1. TF in Inﬂammation. sTF1-219 induces inﬂammatory
arthritis [80], which is characterized by elevated plasma IL-6
and paw swelling accompanied by ﬁbrin overproduction and
platelet aggregation. TF mediates IL-1β-induced vascular
permeability, an inﬂammatory index [81]. Conversely, TF
deﬁciency reduces inﬂammation [82]. The ability of anti-
TF Ab to prevent septic shock [83] and depress macrophage
expression of adhesion molecule CD18 [84] is consistent
with the proinﬂammatory function of TF.
5.1.2. FVIIa in Inﬂammation. Elevated plasma level of FVIIa
shows signiﬁcant correlations to CRP and IL-6 expression
[85],whileFVIIdeﬁciencyprotectsfromacuteinﬂammation
[86]. Administration with recombinant FVIIa enhances IL-6
and -8 productions in healthy human subjects [87].
5.1.3. FXa in Inﬂammation. FXa/PL infusion increases IL-6
andCRPinbaboons[88].FXainducesIL-6[89],IL-8,MCP-
1, ICAM/VCAM, and E-selectin expressions [90]. Consistent
withthenotionofproinﬂammatoryFXa,ZK-807834,anFXa
inhibitor, blocks IL-6 elicitation [89].
5.1.4. FIIa in Inﬂammation. FIIa with ﬁbrin (ogen) depen-
dency induces macrophage adhesion and the production of
IL-6 and MCP-1 [91]. FIIa signaling elicits IL-6 [92], IL-8
[93], MCP-1 [93], VEGF [94, 95], and ICAM/VCAM expres-
sion [96]. FIIa activates platelets releasing proinﬂammatory
serotonin, histamine, and eicosanoid precursors as well as
adhesion molecules [97].
5.1.5. Fibrin in Inﬂammation. Fibrin clot per se is proin-
ﬂammatory.FibrinenhancesnotonlyIL-1βproduction[98],
but also NF-κB activation (a hallmark of inﬂammation) to
induce the expression of ICAM-1 and IL-8 [99], which has
been proposed to be mediated by Toll-like receptor-4. D-
dimers elicit the synthesis [100]a n dr e l e a s e[ 100, 101]o f
IL-1β a n dI L - 6 ,w h i l ef r a g m e n tDo rE[ 101] stimulates
IL-1β secretion. FBG degradation product D elevates IL-
1t ou p r e g u l a t eI L - 6p r o d u c t i o n[ 102]. Fibrin fragment E
enhances IL-6 production [103].
5.2. Protease-Activated Receptor (PAR) Mediates Inﬂamma-
tion. PARs functioning as molecular switches dictate cross-
talks of hypercoagulable states with inﬂammatory outcomes
(Figure 2). PAR expressed ubiquitously in diﬀerent cell types
belongs to the superfamily of GPCR; there are four major
isoformsofwhichtheexpressionisnotaﬀectedbyexogenous
LPS, TNF-α,I L - 1 β,o rI F N - γ. PAR activation by their
corresponding activating peptides triggers inﬂammation [4,
104–106]. For instance, PAR-1 [107]/-2 [107–109]/-4 [107]
a c t i v a t i o n sl e a dt oe n h a n c e dp r o d u c t i o no fI L - 6 / 8a n dI L -
1β [110]. PAR-2 agonists induce TNFα [111] and IL-8 [112]
secretion,whilePAR-1deﬁciencyreducesinﬂammation[82].
The receptor activation involves a proteolytic cleavage of
the extracellular domain, resulting in the formation of a new
N terminus that in turn acts as a tethered ligand to interact
with exoloop 2Glu260 and then activate heterotrimeric
G proteins, triggering an array of intracellular signaling
cascade. For instance, the involved sequences of PAR-
1 (TLDPR41S42FLLRNP) and PAR-2 (SSKGR36S37LIGKY)
are cleaved between R and S by serine proteases such as
FIIa that also cleaves PAR-3 (TLPIKTFRGAP) and PAR-4
(LPAPRGYPGQV) at K/T and R/G,r e s p e c t i v e l y[ 113].
The ability of PAR per se to mediate inﬂammatory
responses [4, 104–106] is readily in line with coagulation-
dependent inﬂammation. It is now clear that PARs transmit
clotting signals for proinﬂammation (Figures 2 and 3(2)).
PAR-1, 3, or 4 is responsible for FIIa signaling. PAR-2 or 3
mediates FXa signaling, while PAR-2 enables FVIIa signaling
(Figure 2, right panel). For instance, PAR-1 transmits FIIa
signal enhancing the expression of IL-6, -8, TNFα,M C P -
1, ICAM-1, PDGF (AB/BB), bFGF, TGFβ,V E G F ,P-selectin,
and Erk/NFκB/iNOS activation, enhanced PI hydrolysis,
COX-2 expression, upregulated [Ca+2]i movement, platelet
aggregation, and macrophage adhesion.Via PAR-2 signaling,
FVIIa activates MAPK and promotes [Ca+2]i movement,
while FXa upregulates the expression of IL-6, -8, MCP-1,
PDGF, VEGF, as well as NFκB and MAPK activation. PAR-
3 mediates FXa and FIIa proinﬂammation for enhanced
cytokine production of IL-6/-8 and adhesion molecule
(MCP-1), while PAR-4 transmits FIIa signaling in leukocyte
rolling and adhesion (for review, see [4]).
Takentogether,itisevidentthatcoagulantmediator(e.g.,
FVIIa, FXa, and FIIa) generation and ﬁbrin production in
the extracellular compartment via PARs signal transduction
and intracellular activations result in the productions of
cytokines, adhesion molecules, growth factors, and other
proinﬂammatory components.
6. Inﬂammation EnsuringTF
Hypercoagulation:ViciousCoagulation-
Inﬂammation Cycle
In addition to the above-mentioned TF divergent role in
coagulation-dependent inﬂammation, TF converges various
inﬂammatory signals in either local or systemic inﬂamma-
tion; not only “extrinsic”, but also the resulting “intrinsic”
onesreverselyturnonandactivatecoagulation(Figure 3(3)).
For instance, rIL-6/8 upregulate procoagulation [114]. The
intramuscular injection of IL-6 results in FIIa generation in
baboons [115]. TNF-α upregulates TF expression in ARDS
[116]. CRP drastically activates TF expression [117]. Viral
infection such as CpG ODN induces TF expression mediated
by TLR-9/MyD88-Erk1/2 pathway with Egr-1 activation
[118]. Long pentraxin-3, an acute inﬂammatory molecule,
upregulates TF expression in lung injury [119]. Conversely,6 International Journal of Inﬂammation
guggulsterone (an anti-inﬂammatory phytosterol) inhibits
TF expression and arterial thrombosis [120], which is
also in favor of such inﬂammation-triggered coagulation
(Figure 3(3)).
Importantly, mounting evidence supports the existence
of such a positive feedback/reversible loop (Figure 3(3)) in a
complete coagulation-inﬂammation cycle [9]. For instance,
FVIIa [121], FXa [121–124], FIIa [17, 31, 124], and PAR-1
[125] promote TF expression. PAR-2 agonists (e.g., trypsin
[126], SLIGKV [126], and proteinase-3 [127]) induce TF
mRNA. Conversely, TF expression is diminished by antico-
agulants(e.g.,TFPI[128–130],FVIIai[131],DX9065a[120],
ZK 807834 [89], low-molecular-weight heparins (LMWHs)
[132], heparin [133, 134], hirudin [135, 136], hirulog [137],
AT III [138], APC [139]), which is consistent with the posi-
tive feedback loop of inﬂammation-dependent coagulation
(Figure 3(2) and (3)) in completing the vicious cycle. In
addition, Wakeﬁeld and his associates have demonstrated
that selectin-deﬁcient mice lacking the activation of the
extrinsic pathway are defective in ﬁbrin production [140].
Thus, it is clear that TF initiates cross-talks of hyper-
coagulable states with inﬂammatory outcomes (Figure 2).
Furthermore, TF hypercoagulability results in enormous
inﬂammation as the result of continuously refueling the
coagulation-inﬂammation cycle ((Figure 3(2) and (3)) upon
gaining its initial momentum such as local or systemic
inﬂammatory/infectious conditions.
7. The Paradigm: Coagulation-Inﬂammation-
Thrombosis Circuit
TF hypercoagulability drives “autocrine” and “paracrine”
signaling, thereby amplifying, refueling, and ensuring
the paradigm: coagulation-inﬂammation-thrombosis circuit
whereitincludesthedirectthromboticactions(Figure 3(1)),
coagulation-dependent inﬂammation (Figure 3(2)), a pos-
itive feedback loop of inﬂammation-triggered TF expres-
sion (Figure 3(3)), and thrombosis-inﬂammation connec-
tion (Figure 3(4)).
7.1. Thrombosis-Inﬂammation Connection (Figure 3(4)) .
Thrombosis and inﬂammation are two major consequences
of blood coagulation, both of which cross-talk and pro-
mote each other. Clinical association of thrombosis with
inﬂammation has been reported in many cases [141]. Such
inﬂammation-thrombosisconnection(Figure 3(4))provides
an alternative pathway that blood coagulation via its inﬂam-
matory consequence indirectly contributes to thrombosis.
Several lines of evidence reveal thrombosis-dependent
inﬂammation based on the ability of ﬁbrin and its fragments
to elicit IL-1β, IL-6, and IL-8 expression [98–103]. Further,
platelet activation/aggregation participates in complement
activation resulting in inﬂammatory responses. P-selectin as
a C3b-binding protein suﬃciently leads to C3a generation
and C5b-C9 formation, which supports a novel mechanism
of local inﬂammation in vascular injury sites [69, 141].
Conversely, in vivo inﬂammation-dependent thrombo-
genesis also exists. IL-8 enhances ﬁbrosis in rats [142]. In
support of this notion, activation and antagonism of proin-
ﬂammatory PARs, respectively, trigger and reduce thrombo-
genesis (for review, see [69]). For instance, PAR-4 activation
[80] and PAR4-activating peptides [143]t r i g g e rp l a t e l e t
aggregation;consistently,PARantagonismattenuatesplatelet
activation/aggregation (for details, see Section 10.6) in line
with such inﬂammation-dependent thrombogenesis. An
earlierstudyhasshownthatP-selectincausesleukocyteaccu-
mulation to facilitate ﬁbrin deposition [144], complement-
ing thrombotic episodes. P/E/L-selectins, ICAM, and VCAM
are responsible for leukocyte adhesion/rolling/recruitment
interacting with platelets and VEC to enhance thrombus
formation [145]. In parallel, selectin-deﬁcient mice lacking
the activation of the extrinsic pathway are defective in ﬁbrin
production [140]. Antibodies to cytokines and adhesion
molecules attenuate venous thrombosis [146]. LYP20, an
antibody against P-selectin, blocks leukocyte adhesion to EC
and platelets [147] and modiﬁes thrombosis [148], and P-
selectin inhibition decreases vein wall ﬁbrosis [149].
In addition, there is a general perception of inﬂamma-
tion-dependent thrombogenesis, which is supported by
the observations that anti-inﬂammatory agents are of
antithrombotic beneﬁts. For instance, nonsteroid anti-
inﬂammatory drugs readily block thrombosis. COX-1
inhibitor such as low doses of aspirin suppresses platelet
aggregation [150]. Similarly, COX-2 inhibition downregu-
lates VEC/leukocyte activation [151].
7.2. The Circuit. Thrombosis-inﬂammation connection
(Figure 3(4)) is integrated into the coagulation-inﬂam-
mation vicious cycle (Figure 3(2) and (3)), thus rount-
ing a complete circuit to link among coagulation, inﬂam-
mation, and thrombosis. Concomitant with suppressed
TF expression by COX inhibitors [35–37], the anti-
inﬂammatory and antithrombotic properties of COX-2
inhibitors [150, 151] seem likely to be in agreement with
the involvement of TF hypercoagulability in driving the
coagulation-inﬂammation-thrombosis circuit. Further,
activated platelets stimulate TF expression [152], while
antiplatelet agent (dilazep) inhibits TF expression [153].
Both observations are in favor of the thrombosis-
inﬂammation connection (Figure 3(4)) being part of
the operative blood coagulation-inﬂammation-thrombosis
circuit. The paradigm has also been observed in lung [154]
and inﬂammatory bowel syndrome [155] while closely
relating to cardiovascular risks [9, 69].
8. Coagulation-DependentEvents:
Thrombosis/Inﬂammation-Associated
Conditions
Mounting evidence reveals that TF hypercoagulability plays
pathogenic roles closely relating to its not only inﬂammatory
butalsothromboticactions.Bydrivingthecircuit(Figure 3),
TF hypercoagulability is readily involved in an array of
metabolic syndromes (e.g., atherosclerosis, hypertension,
diabetes II, and obesity) and other clinical manifestationsInternational Journal of Inﬂammation 7
(e.g., cancers, antiphospholipid syndrome (APS), and fetal
loss).
8.1. TF in Sepsis/DIC. Hypercoagulation is often observed
in septic shock including endotoxemia or systemic inﬂam-
matory responses after trauma, which mainly results from
TF overexpression [156–158]. The ability of TF blockade
to ease septic shock [83] or organ injury [159] points to
a fundamental pathogenic role of TF in sepsis. Extrinsic
infection/inﬂammation upregulating TF expression medi-
ates enormous local or systemic intrinsic inﬂammation
as well as a thrombotic condition via the operational
circuit (Figures 2 and 3). A common manifestation presents
DIC, an acquired disorder with hemostatic imbalance;
excessive FIIa formation leads to ﬁbrin deposition in
microcirculation and consequent ischemic organ damage.
Thus, such autocrine or paracrine TF signaling could lead
to substantial tissue damages or multiple organ failure.
8.2. TF in Cancers. TF overexpression has been reported
in ovarian cancer [160], endometriosis [161], breast cancer
[162], nonsmall cell lung carcinoma [163], prostate cancer
[164], pancreatic cancer [165], melanoma [166], colorectal
cancer [167], gastric cancer [168], esophageal cancer [169],
hepatocellular carcinoma [170], brain tumor glioblastoma
[171], leukemia [172], and lymphoma [173]. Accordingly,
TF overexpression could be considered a biomarker for solid
tumors [174].
The roles of TF in cancer have been demonstrated with
severalfold relevance in relation to thrombotic condition,
tumorigenesis per se and TF signaling (i.e., coagulation-
dependant inﬂammation). Cancer linked with hypercoag-
ulability and thrombotic risk has long been recognized
by Armand Trousseau since 1865. The American Society
of Hematology calling for a special session on “cancer
and thrombosis” addresses its complex clinical interface
of prothrombotic association with malignancies and pro-
phylactic approaches. Cancer certainly could be recognized
as a prothrombotic risk factor, leading to, for instance,
venous thromboembolism and its complication of pul-
monary embolism and mortality. Namely, cancers readily
induce thrombosis [175]. Enhanced TF expression typically
accounts for the mode of mechanism of thrombosis accom-
panied by suppressed TFPI [176] and defective APC antico-
agulation system. Not only tumor cellular membrane-bound
TF, but also microparticle-associated TF [177] links cancer
to thrombosis. In addition, the similar hypercoagulable state
exists in cancer stem cells [178].
The critical role of TF in tumorigenesis is supported by
the observations that inhibited TF expression blocks tumor
growth, metastasis [179], angiogenesis [180], cell invasion
[181], and many other cancer characteristics. TF per se plays
important roles in cell proliferation, tumor development,
and progression apart from the accompanying coagulation-
dependent inﬂammatory environment including MMP-9
[182],growthfactors(VEGF,EGF,PDGF,etc.),andadhesion
molecules certainly promoting “autocrine” tumorigenesis.
Either VEGF or EGF in trun stimulates sustained TF
expression [27, 28]. PTEN loss and tumor hypoxia readily
induce TF expression [183], which could highlight TF as a
major player in cancer progression.
Tumor-expressed TF promotes growth by increasing cell
survival and/or angiogenesis. TF and VEGF expressions
mutually enhance each other [184], where VEGF is a
known main angiogenic factor of cancer characteristics. TF
cytoplasmic domain has been shown to be critical for VEGF
expression [185]; conversely, VEGF causes TF promoter
activation and involves gene upregulation with transcription
factor NFAT involvement [28]. It is of particular inter-
est to note that the serine phosphorylated cytoplasmic
domain inhibits cellular cytotoxicity [186], thereby leading
to increased tumor survival and metastatic rate. In addition,
increasedTFcytoplasmicdomainphosphorylationandPAR-
2 activation signiﬁcantly correlate to cancer relapse [181].
Thus, a cooperation of the phosphorylated TF cytoplasmic
domain with protease signaling could account for diverse
contributions of TF to metastasis and angiogenesis [81, 187].
As the proceeding of TF-initiated extrinsic pathway, the
resulting FIIa generation and ﬁbrin production are of proan-
giogenesis. Furthermore, TF/FVIIa activates BcL2 [188],
and FXa inactivates caspase-3 [189], both of which inhibit
apoptosis. TF/FVIIa/FXa ternary complex possibly mediated
by PAR-1/2 readily induces Erk1/2, Akt/PKB, and mTOR
activation, all of which enhance the downstream signaling
target phosphorylation for cancer cell undergoing antiapop-
tosis [190] and cell migration [191]. FIIa-PAR signaling
in metastasis [192]/angiogenesis [94] and TF/FVIIa/PARs
signaling in tumor growth [193] are also evident. FIIa could
be recognized as a tumor growth factor [192, 194], which is
accompanied by the enhanced tumor cell cycle mediated by
downregulation of p27Kip1 and upregulation of Skp2 and
MiR-222 [195]. FIIa is also able to upregulate cathepsin D
which enhances angiogenesis, growth, and metastasis [196].
FIIa activates ﬁbrinolysis inhibitors (e.g., TAFI [74]a n dP A I -
1[ 76]), further promoting cancer progression [197].
8.3. TF in Obesity. TF gene overexpression in obese has
been reported for more than a decade [198, 199]a c c o m -
panied by upregulated PAI-1, angiogenesis, cell adhesion,
a n ds of o r t h ,a l lo fw h i c hc o u l ds t e mf r o mT Fh y p e r -
coagulability. Inﬂammation has been proposed to engage
in obesity development [200] ,w h i l el e s si sc l e a ra b o u t
the precise role of thrombosis per se in obesity. With
the functional coagulation-inﬂammation-thrombosis circuit
(Figure 3), triggered inﬂammation constitutes the patho-
genesis of obesity with manifestation including diabetes
and cardiovascular risks (e.g., atherosclerosis, hyperten-
sion).
TFsignaling(Figure 2)setsupinﬂammation,inpartwell
accounting for elevated levels of IL-6 [200, 201], IL-8 [201],
and TNFα [200] detected in obese subjects. Among which,
either local or systemic inﬂammation (TNFα) signiﬁcantly
contributes to obesity [202] .B a s e du p o nh i g hl e p t i na n d
low adiponectin levels in obesity, the ability of leptin [30]
or adiponectin [47], respectively, to augment or suppress TF
synthesis could imply a mechanistic role of TF in developing
inﬂammatory obesity. Furthermore, the involvement of8 International Journal of Inﬂammation
PPARα agonists [52]/activators [53] in downregulating TF
expression also likely underlines a positive TF function in the
process of inﬂammatory obesity.
8.4. TF in Diabetes. Diabetes including type I and II is a
hypercoagulable state [203] with elevated plasma levels of
clotting factors (FVII, FVIII, FX, FXI, FXII), D-dimers, and
TAT accompanied by decreased AT III, heparin cofactor II,
or APC, presenting a thrombotic condition.
Under hyperglycemia, excessive plasma glucose
nonenzymatically conjugates with plasma proteins (e.g.,
hemoglobins) to form AGE. AGEs through their receptors
exhibit biological damage in various tissues such as
renal failure and vascular complications. For instance,
hyperglycemia induces damage to vascular endothelial cells,
which is mediated by the complex activation of MAPK,
PKC, NF-κB, and ICAM-1, primarily causing hemostatic
alterations [204].
Increased circulating AGEs enhance TF expression [205],
making diabetes a hypercoagulable and thrombotic condi-
tion [203, 205, 206]. Platelet TF in diabetes II appreciably
increases [207]; increased FIIa and FXa generations are also
foundindiabeticplatelets,enhancingthethromboticnature.
TF overexpression essentially promotes diabetes progression
as well as its manifestation. As a consequence of diabetic TF
hypercoagulability, elevated inﬂammatory mediators elicit
cardiovascular complications including atherosclerosis. It is
estimated that 80% diabetic patients die from a thrombotic
disease and 75% of which result from cardiovascular compli-
cations [208]. Diabetic complications are more threatening
than hyperglycemia per se; accordingly, relief of hypercoag-
ulability could become far more important than glycemic
control. Population-based clinical trials (ACCORD [209],
ADVANCE [210]a sw e l la sV A D T[ 211]) have demonstrated
no beneﬁt to cardiovascular risk in diabetes II upon glycemic
control with signiﬁcant low AGE (e.g., glycated hemoglobin
<6%) for 2–3.5 years. Furthermore, rosiglitazone sub-
stantially lowering glycemia surprisingly increases the risk
of myocardial infarction and death from cardiovascular
causes [212]. For diabetic cardiovascular events, one could
not expect that glycemic control per se signiﬁcantly and
promptly reverses the downstream damages done by AGEs.
Apparently, nonglycemic factors (e.g., hypercoagulability,
hypertension, and hyperlipidemia) play important roles in
such complications.
Apart from thrombotic natures, TF could assume a
pathogenic role in diabetic progression in a close relation
to inﬂammatory process [213, 214]. It is likely that TF
signaling (Figure 2) through the coagulation-inﬂammation-
thrombosis circuit (Figure 3) operating in diabetes could
well be responsible for insulin resistance. Proinﬂammatory
mediator TNFα is known to promote insulin resistance in
which serine phosphorylation of insulin receptor substrate
(IRS) is encouraged. As a consequence of preventing insulin
downstream IRS tyrosine phosphorylation, TNFα thereby
blocks insulin signal transduction [215]. In sharp contrast
to TNFα negative eﬀects on insulin action, adiponectin pos-
itively enhances insulin sensitivity, and hypoadiponectine-
mia accordingly leads to insulin resistance [215]. Notably,
anti-inﬂammatory adiponectin suppresses TF expression
[47], which could be in support of the role of TF in
diabetes pathology. From the viewpoint of PPARα activation
improving insulin sensitivity, the observations of PPARα
agonists [52]/activators [53] downregulating TF expression
also likely point to positive TF function(s) in insulin
resistance involving inﬂammatory diabetes development.
In summary, TF function has twofold signiﬁcance in
diabetes. TF not only dictates diabetic hypercoagulable
nature and thrombotic outcomes [203], but also overlays
its signaling in proinﬂammation (Figure 2) for insulin
resistance. The ability of insulin [40] or an antidiabetic
agent(metformin)[59]toattenuateTFexpressionseemingly
reinforces a key pathogenic role of TF in diabetes.
8.5. TF in Cardiovascular Complications. Cardiovascular
complications are a group of disorders closely associated
with either inﬂammation or thrombosis or both. In these
regards, it is not surprising that TF plays a major role in
their pathogeneses [9]. TF overexpression, often correlated
togain-of-functionofTFpromoterpolymorphism(A603G),
promotes the development of cardiovascular diseases [216].
It has long been established that TF participates in the
phase III of plaque rupture [217] during atherogenesis.
TF expression is upregulated in atherosclerotic plaques of
patients with unstable angina and myocardial infarction
[218].
TF hypercoagulability driving the coagulation-
inﬂammation-thrombosis circuit (Figure 3) readily extends
its diverse consequences to cardiovascular complications and
vascular diseases [219] including arrhythmias [58], arterial
hypertension [220], hypertrophy [221], ACS [222, 223],
andatrial ﬁbrillation (AF) [224], TF hypercoagulability with
elevated proinﬂammatory cytokines (Figure 2)c o u l di n
part well contribute to atherosclerosis known as chronic
inﬂammatory disease [217]. In cultures, recombinant
TF induces cellular apoptosis with increased caspase-3
activity and nuclear location of p53 while increasing cellular
proliferation/hypertrophic growth [221]. As a consequence
of accelerated cardiomyocyte turnover, TF could contribute
to the induction and progression of cardiac hypertrophy.
Angiotensin II stimulates TF synthesis [220], mediating
hypertensive action. Histamine augments TF expression,
accounting for its action in ACS [225]. In conjunction
with its eﬀects on endothelial damage/dysfunction and
angiogenic actions [224], TF upregulation could well be
involved in a thrombogenic state of AF [224].
In contrast, TF deﬁciency in mice shows cardiac ﬁbrosis
[226, 227] largely based upon TF functions in normal
extracellular cardiac homeostasis, extracellular matrix regu-
lation, and vascular maintenance [227]. Apparently, cardiac
bleeding/hemorrhages in TF deﬁciency certainly encourages
itsﬁbrosis[226]wherePAinvolvementcouldalsobeensured
by insuﬃcient FIIa generation [74–76]. It awaits further
conﬁrmation in human conditions.
8.6. TF in Autoimmune Disorder: Antiphospholipid Syndrome
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presence of aPL including lupus anticoagulants, anticar-
diolipin antibodies, and anti-β2-glycoprotein-1 (β2GPI)
antibodies. It is proposed that TLR-4 mediates anti-β2GPI-
induced TF expression [228]. Alternatively, TF overexpres-
sion results from APS-associated complement activation.
aPLactivatescomplementviatheclassicalpathway;activated
complement (e.g., C5a) drastically stimulates TF synthesis.
This autoimmune thrombophilic condition is largely due
to enhanced coagulation (e.g., TF overexpression) accom-
panied by attenuated downregulation of blood coagulation
(e.g., inhibited APC, TFPI, and AnxA5) and suppressed
ﬁbrinolysis. Increased microparticles and TF expression are
found in APS with prothrombotic conditions of various
manifestations, most commonly venous and arterial throm-
boembolism and recurrent pregnancy loss.
In addition, TF could play a pathological role in APS
manifestation. It is not surprising if APS of TF overexpres-
sion also presents a hyperinﬂammatory condition in view
of the paradigm of coagulation-inﬂammation-thrombosis
circuit (Figure 3). Apart from that aPL-induced complement
activation contributes to inﬂammation [229], TF signaling
could well account for increased TNFα [230–232]p r o d u c -
tion as major proinﬂammation reported in APS patients
[233] in which TNFα also seems to be responsible for its
manifestation: fetal damage [232].
8.7. TF in Miscarriage. Miscarriage including fetal death,
preeclampsia, and intrauterine growth restriction often
closely links to APS involving complement and angiogenic
actions. During trophoblast diﬀerentiation, aPL activates
complement via the classical pathway. Complement activa-
tion (C3 and C5a) directly mediates placental injury and
causes fetal loss and growth restriction, resulting from an
imbalance of angiogenic factors (e.g., VEGF and placental
growth factor) as well as their corresponding receptors that
are required for normal placental development [234].
Alternatively, TF overexpression is triggered by aPL-
induced complement activation, and TF signaling fulﬁlls
such miscarriage/placenta damage/fetal injury. For instance,
recent research demonstrates that neutrophil activation by
TF/FVIIa/PAR-2signaling[235]mediatesaPL-inducedpreg-
nancy complication. In fact, TF on neutrophils and mono-
cytes is a critical mediator in trophoblast injury and embryo
damage in aPL-dependent or independent pregnancy loss
[236]. Rapid increases in decidual and systemic TNF-α level
are also responsible for fetal death/loss [232], which could
be in line with TF signaling (Figure 2) playing a pathogenic
role. Further, FIIa-induced platelet activation/aggregation
activates complements, possibly conferring the direct fetal
damage [234].
Anti-TF mAb prevents aPL-induced pregnancy loss
[234], while statins [237, 238] may be a good treatment
for women with recurrent miscarriages and intrauterine
growth restriction. These clinical studies are consistent with
a pathogenic role of TF in APS-induced fetal damage.
8.8. TF in Wound Healing. Wound, including diabetic foot,
healing process generally consists of three phases (inﬂamma-
tory, proliferative, and remodeling phases) that continuously
overlap one another during the process. Hemostasis initiates
angiogenesis-dependent wound healing. TF overexpression
often occurring after wounding, trauma, or surgeries in
part accounts for hypercoagulability encouraging wounding
healing [239–241]. Given that inﬂammation involved in the
initial phase, such “autocrine” or “paracrine” TF signaling
essentially ensures ﬁbrin matrix formation, angiogenesis,
production of growth factors (VEGF, PDGF, bFGF, TGFα/β,
etc.), adhesion molecules, and so forth, (Figures 2 and 3), all
of which signiﬁcantly contribute to wound healing process.
8.9. TF in Development. Limited evidence reveals that TF
extracellular domain is essential for embryogenesis [242–
244], which is believed to be mediated by TF-dependent
FIIa generation and PAR-1 activation. Thus, TF serves as
an important morphogenic factor during embryogenesis.
Apparently, TF signaling with FVIIa, FXa, and FIIa gen-
eration for PAR activation/transduction triggers an array
of biological events as a consequence of proinﬂammation
(Figure 2, right panel), among which growth factors (EGF,
VEGF, PDGF, bFGF, etc.) could play major roles in develop-
ment [245]. Consistently, inactivation of TF gene results in
embryonic lethality in a murine model [243]. It is said that
TF expression coordinated with TFPI, ATIII, and FVII levels
c o u l db ec r i t i c a li ne m b r y o n i cd e v e l o p m e n t[ 246].
8.10. TF in Other Diseases. TF expression is often upregu-
lated by an antibody to platelet factor 4 (PF4) upon a long
exposure/treatment of heparin [247]. In heparin-induced
thrombocytopenia, PF4 also impairs APC activity, making a
pronounced hypercoagulable and prothrombotic condition.
TF overexpression in adult onset asthma signiﬁcantly corre-
lates to the gain-of-function of TF promoter polymorphism
(A603G) [216].
Concerning innate immunity and acute inﬂammation,
complement activation is of TF relevance. Complement
activation,especiallyC5a,upregulatesTFexpression,thereby
extending to a broad spectrum of immune consequences
[248]. TF overexpression exhibits “paracrine” signaling for
fulﬁlling innate immunity regardless of TF expression by
neutrophils remaining debatable. Similarly, TF overexpres-
sion is observed in bacterial (pneumonia [249], Helicobacter
pylori [250]), viral (HIV) [251], or parasite (malaria) [252]
infection.
In response to surgical procedures, enhanced TF synthe-
sis is reported in major surgeries such as hip replacement,
cardiopulmonary bypass (CPB) [253] or transplantation
[254–256]. Upon tissue injury, exposure to protein disulﬁde
isomerase and PS readily activates TF [10–12] and its
signaling. It is plausible that TF hypercoagulability in part
accounts for postsurgical inﬂammatory responses.
With regard to lifestyles, smoking upregulating TF
expression apart from its apparent free radical inhalation
elicits diverse health problems including cardiovascular and
cancer risks. High-fat diets [257], oral contraceptives [15,
258], and estrogen replacement [21, 259] also promote TF
expression, possibly driving the circuit (Figure 3)f o rd i v e r s e
clinical manifestations in relation to inﬂammation or/and
thrombosis.10 International Journal of Inﬂammation
In addition, TF overexpression is associated with other
pathological conditions such as liver cirrhosis [260], synovial
inﬂammation [261], sickle cell anemia [262], or hepatic
necrosis during cholestasis [263]. These pathological con-
ditions likely result from the coagulation-inﬂammation-
thrombosis circuit (Figure 3); the precise mechanisms of
a c t i o nh o w e v e rr e m a i nt ob ed e ﬁ n e d .
9.Noncoagulation-MediatedTF Roles
The signaling function of TF cytoplasmic domain has been
demonstrated although its biochemical mechanism remains
unclear. For instance, cross-talk between intracellular TF
domain with integin α3β1p r o m o t e sc e l lm i g r a t i o n[ 264],
while the cytoplasmic domain possibly upon phosphory-
lation of the three serine residues causes hyperchemotaxis
[265]. The cytoplasmic domain contributes to renal albu-
min retention, and its renal expression protects against
proteinuria. Consistently, the absence of the cytoplasmic
domain is associated with increased albuminuria, increased
spontaneous glomerular TNFα production, podocyte eﬀace-
ment/inﬂection, reduced podocyte numbers, resulting in
albuminuria and proteinuria [266]. For cancer progres-
sion/relapse, increased cytoplasmic domain phosphorylation
signiﬁcantly correlates to metastasis and angiogenesis [267].
It is proposed that the cytoplasmic domain per se is
critical for VEFG expression [185], an important angiogenic
component in tumorigenesis.
10. Antagonisms against TF Signaling-Evolving
Thrombotic or Inﬂammatory Events
In view of the paradigm of coagulation-inﬂammation-
thrombosis circuit (Figure 3), any interruption of the cir-
cuit is accordingly expected to exert broad antagonism
against hypercoagulation, inﬂammation, thrombosis, and
their complications. Table 1 lists some typical examples of
targeting TF hypercoagulation for ﬁghting diverse patho-
logical conditions in cell cultures, ex vivo, animal studies,
or clinical trials. Strategies targeting TF signaling include
TF suppression, general anticoagulation, FVIIa inhibition,
FXa inhibition, FIIa inhibition, PAR antagonism, and many
others.
10.1. TF Suppression. Inhibited TF synthesis readily leads to
many clinical applications for easing pathological conditions
including inﬂammation, thrombosis, and cardiovascular
dysfunctions. For instance, vitamin D3 deﬁciency often
exists in APS; consistently, vitamin D3 inhibits transcription
factors (e.g., AP-1 and NFκB) to reduce TF overexpression
for easing APS-induced thrombosis [268]. 1, 25(OH)2
D3 analogs are also used for immunomodulation and
antineoplastic therapy of leukemia [50]. A novel NO-
releasing statin derivative exerts antiplatelet/antithrombotic
activity [269]. Indobufen, through a thromboxane-mediated
mechanism, exhibits antagonisms against atherothrombo-
sis [57]. Amiodarone inhibiting TF translation attenuates
arterial thrombosis including coronary artery thrombosis
as much as ventricular arrhythmias [58]. Nicotinamide
inhibits coagulation and inﬂammation, resulting in anti-
inﬂammation with reduced IL-6 and CD11a in sepsis or
DIC [41]. ACE inhibitors oﬀsetting ATII-induced TF over-
expression reduce the risk of recurrent myocardial infarction
in patients with left ventricular dysfunction [46]. Ethyl
pyruvate inhibiting TF mRNA expression shows combined
anti-inﬂammatory and anticoagulant eﬀect [44]. DMSO
inhibiting thrombus formation and vascular smooth muscle
cell activation could improve acute coronary syndromes
[45]. Liver X receptor agonists attenuate atherothrombosis
[54]. A hairpin ribozyme inhibiting TF gene expression
and TF mRNA shows antithrombotic action [63]. Hydrox-
yurea has antithrombotic activity [43], while pentoxifylline
attenuates DIC [55]. Adiponectin could prevent endothe-
lial dysfunction and atherogenesis in acute coronary syn-
drome [47]. PPARα agonists [52]/activators [53] reduce the
thrombogenicity of atherosclerotic plaques. TF suppression
by adiponectin [47]o rP P A R α activation [52, 53]c o u l d
also constitute antagonism against diabesity. Metformin, an
antidiabetic agent, suppresses the production of TNFα [59],
a known factor for insulin resistance [213–215]. Antisense
oligonucleotide blocking TF expression prevents leukocyte
adhesion following renal ischemic reperfusion injury [66,
270]. COX inhibitors readily show anti-inﬂammation [152,
153] as well as antithrombosis. Red wine phenolics and
quercetin improve cardiovascular health and prevent CHD
[56]. Guggulsterone suppresses TF expression together with
anti-inﬂammation and antagonism against arterial throm-
bosis [120]. HMG-CoA reductase inhibitors (e.g., pravas-
tatin) prevents APS-mediated miscarriages and placental
and fetal injury [33, 34, 237, 238], in addition to the
general anti-inﬂammatory eﬀects of statins on lowering
CRP, IL-1β, IL-6, and so forth. However, little is known
and remains inconclusive about the antithrombotic/anti-
inﬂammatory relevance of targeting TF synthesis by various
inhibitions of intracellular signaling kinases (e.g., MAPK,
PKC) or transcription factors (e.g., NFκB); the signaling
downregulation per se already shows anti-inﬂammation [4].
Interestingly, paclitaxel exhibits anticancer activity [38].
COX-2 inhibitors show the prevention of colorectal cancer
[271],whileall-transretinoicacidinhibitingcancerprocoag-
ulation could of beneﬁt to leukemia [49]. shTF RNA inhibits
breast cancer growth/angiogenesis in vivo independent of
VEGF regulation in mice [62], and TF RNAi antagonizes
metastasis [272].
10.2. FVIIa Inhibition. FVIIa inhibition readily shows antag-
onism against inﬂammation. Recombinant nematode anti-
coagulantproteinc2(NAPc2),anovelinhibitorforTF/FVIIa
complex, diminishes coagulation-dependent IL-6 and IL-
8 productions [87]. Active site-inhibited FVIIa depresses
LPS-inducible plasma levels of TNF-α [273], IL-6 [273–
275], and IL-8 [274, 275]. FVIIai suppresses sTF-induced
inﬂammation in an in vivo model [80]. A small molecule
BCX-3607 (TF/FVIIa inhibitor) also decreases IL-6 level in
an endotoxemia mouse model [276].
Hemextin AB complex, a snake venom protein complex,
directly inhibits FVIIa catalytic activity for anticoagulationInternational Journal of Inﬂammation 11
Table 1: Targeting TF-initiated coagulation and signaling consequence for easing clinical events.
Strategy and agent Antagonism against
TF suppression
HMGCR inhibitors Inﬂammation; thrombosis; miscarriage; APS; cancer growth
COX inhibitors Inﬂammation, APS; thrombosis; miscarriage; cancers
Vitamin D3 APS; thrombosis; cancer
Amiodarone AT; arrhythmia
Ethyl pyruvate Inﬂammation; coagulation
NO Platelet activation; thrombosis
Indobufen AT
Hydroxyurea Thrombosis
RNAi Metastasis
DMSO ACS
Adiponectin Atherogenesis; diabetes; ACS
Hairpin ribozym Thrombosis; I/R injury
TF sh RNA Breast cancer growth/angiogenesis
Metformin Diabetes II
Liver X receptor agonists AT
Paclitoxel Cancers
Antisense TF ODN I/R injury
ACE inhibitors MI
Nicotinamide Sepsis; DIC; coagulation; inﬂammation
PPARα activation Obesity; diabetes
Guggulsterone Inﬂammation; AT
ATRA Leukemia; CHD
Phenolics/resveratrol CHD
FVIIainhibition
BcX-3607 Thrombosis; inﬂammation
FVIIai Colorectal metastasis; inﬂammation; thrombosis/MI
rNAPc2 Coagulation; inﬂammation; angiogenesis; tumor growth
Hemextin AB Coagulation
BMS593214 AT; VT
PN7051 Thrombosis
PHA-798 Thrombosis
FFR-rFVIIa Inﬂammation; thrombosis; metastasis
FXa inhibition
Fondaparinux DVT; VTE; PE
Enoxaparin Inﬂammation; AT; VT
WX-FX4 Metastasis/tumor growth/angiogenesis
DX-9065a Inﬂammation; platelet aggregation; DIC; tumor proliferation
TAK-442 Coagulation; VT
ZK-807834 Inﬂammation; AT; VT
Oral rivaroxaban AF; VTE
Oral GW 813893 Thrombosis
Oral BMB344577 Cancer proliferation
Oral apixaban Platelet aggregation
LMWH AVE5026 AT; VT; coagulation
Oral DU176b Thromboembolism; coagulation12 International Journal of Inﬂammation
Table 1: Continued.
Strategy and agent Antagonism against
Oral sulfanilamide Coagulation
Oral DPC423 Thrombosis
Oral YM-75466 Thrombosis
MCM09 Cancer metastasis
Oral BAY597939 Thromboembolism
Ixolaris Tumor growth; angiogenesis
NAP5 Coagulation
Tinzaparin Metastasis
SamOrg123781A AT
rTAP (rAST) Thrombosis; restenosis
Rivaroxaban Stroke; AF
FIIainhibition
FM-19 Platelet activation; ACS; tumor growth
Dabigatran etexilate Breast cancer progression
Argatroban DVT; VTE; tumor migration/metastasis
Heparin Inﬂammation; DVT; VTE; pregnancy loss; metastasis
Foypan Metastasis
Ximelagatran DVT; VTE; AT
Hirudins Inﬂammation; DVT; VTE; AT
Org 42675 AT
PAR blockade
SCH 7979 Inﬂammation; platelet aggregation; I/R injury; cancer cell
motility/metastasis/angiogenesis
RWJ 56110 Platelet aggregation; thrombosis
RWJ 58259 Plateletaggregation;vascularocclusion;neointimalthickness;
restenosis; thrombosis
PAR-1 antibody Platelet aggregation
PAR-2 mAb Joint inﬂammation
ENMD-1068 Joint inﬂammation
P4pal DIC; thrombocytopenia; I/R injury
YD-3 Platelet aggregation
SFLLR Platelet aggregation
FR 171113 Platelet aggregation; AT
TH146 Platelet aggregation; thrombosis
FSLLRY-NH2 Inﬂammation
Miscellaneous
TFPI Inﬂammation; pulmonary ﬁbrosis; VT; pneumonia; RA;
cancer; apoptosis
APC Inﬂammation; AT; VT; sepsis; metastasis; apoptosis
AT-III Inﬂammation; thrombosis; metastasis; angiogenesis
Dilazep Platelet aggregation; APS
CNTO 859 Tumor initiation/growth/angiogenesis
Anti-TF mAb Septic shock; DVT; AT/VT; miscarriage
Oral warfarin Inﬂammation; thrombosis; metastasis; tumor growth
n-3 FA Inﬂammation
APS: antiphospholipid syndrome; ACS: acute coronary syndromes; AF: atrial ﬁbrillation; ATRA: all-trans retinoic acid; AT: arterial thrombosis; CHD:
coronary heart disease; COX: cyclooxygynase; DIC: disseminated intravascular coagulation; DVT: deep vein thrombosis; HMGCR: HMGCoA reductase;
MI: myocardial infarction; VT: venous thrombosis; VTE: venous thromboembolism; PE: pulmonary embolism; RA: rheumatoid arthritis; I/R injury,
ischemia/reperfusion injury.International Journal of Inﬂammation 13
[277]. Active site-blocked FVIIa [278] and BMS-593214
[279] provide cardioprotection and carotid arterial and
venous thrombosis. Bolus of FFR-rFVIIa reduces thrombus
and ﬁbrin deposition in A-A shunt rat model [280]. FFR-
rFVIIainhibitsexvivoﬁbrindepositioninpatientsundertak-
ingpercutaneouscoronaryintervention[281].DEGR-rFVIIa
prevents thrombus formation in whole blood [282]. Simi-
larly, an active site-blocked FVIIai attenuates ﬁbrin/platelet
deposition [283]. By altering TF/FVIIa binding and inhibit-
ing its activity, sTF mutant reduces arterial thrombosis in
guinea pigs [284]. A cyclic dodecapeptide (PN7051) derived
from the second EGF-like domain of FVII interferes with
TF/FVII/FX complex to attenuate ﬁbrin deposition, platelet-
ﬁbrin adhesion and platelet-thrombus formation [285].
PHA-798 diminishes thrombus formation in primates [286].
It remains to be determined concerning the antithombotic
application of rNAPc2.
Remarkably, it has also been documented that FVIIa
inhibition exhibits anticancer actions. rNAPc2 [287, 288]o r
active site-blocked FVIIa [289] inhibits cancer metastasis,
angiogenesis, and/or tumor growth.
10.3. FXa Inhibition. A growing list of oral FXa inhibitors
is developed and available; animal or clinical studies show
therapeutically anti-inﬂammatory applications: LMWH,
enoxaparin, or DX9065a suppressing P-selectin, TNF-
α,I L - 6[ 290], or MCP-1 [291] expression. ZK-807834
attenuates FXa-induced IL-6 production [89]. LMWH
(AV 526 [292]) and direct FXa inhibitors (biarylmethoxy
isonipecotanilides [293]) are antagonistic against AT/VT
and coagulation. LMWHs including Fondaparinux [294],
Enoxaparin [295], Bemiparin [296], Tinzaparin [297],
Fraxiparine [298], Reviparin [299], and Dalteparin [300]
exhibit clinical beneﬁts for arterial/venous thrombosis,
venous thromboembolism (VTE), and DVT; all LMWHs
are able to markedly inhibit platelet aggregation in whole
blood. SamOrg 123781A has recently been evaluated for its
antithrombotic application with reduced platelet adhesion
and thrombus formation in pigs [301]. Recombinant anti-
stasin (rATS) or tick anticoagulant peptide (rTAP) reduces
restenosis in balloon angioplasty rabbits [302], and rTAP
reduces TF/FVIIa-dependent thrombus formation in vitro
[303]. DX-9065a depresses platelet aggregation [304]a n d
leukocyte adhesion to EC [305] while providing eﬀective
protection against tumor-induced DIC [306]. Newly devel-
oped TAK-442A shows antithrombotic and anticoagulant
activities against venous thrombosis [307]. Orally active
amidinoaryl propanoic acid reduces platelet deposition and
ﬁbrin accumulation in venous-type thrombus in baboons
[308]. ZK-807834 inhibits arterial thrombosis [309]a sw e l l
as venous thrombosis in vascular injury rabbits [310]a n d
electrolytic injury canines [311]. SF 303 and 549 inhibit A-V
shunt-induced thrombus formation in rabbits [312]. Orally
active YM-75466 inhibits thrombosis in mice [313]. FXV673
inhibits thrombus formation in canines [314]. Orally active
pyrazole DPC423 attenuates electrically induced carotid
artery thrombosis in rabbits [315]. Isoxazolines and isoxa-
zoles prevent A-V shunt thrombosis [316], while RPR120844
reduces venous thrombosis in rabbits [317]. Rivaroxaban
preventsandtreatsvenousthromboembolismandisusedfor
stroke prevention in AF [318]. GW813893 is of antithrom-
botic therapeutic beneﬁts [319]. Apixaban inhibits platelet
aggregation [320]. DU-176b is considered a new anticoagu-
lant for the prophylaxis and treatment of thromboembolic
diseases [321]. Oral BAY 59-7939 is for the prevention of
venous thromboembolism [322]. Many more direct FXa
inhibitors await clinical studies for their anti-inﬂammatory
and antithrombotic applications.
Anticancer activity through direct FXa inhibition is
also reported. WX-FX4 eﬀectively inhibits metastasis/tumor
growth/angiogenesis and prolongs survival [323]. LMWH
Tinzaparin shows antimetastatic eﬀect [324]. Ixolaris is able
to block primary tumor growth and angiogenesis [325]. DX-
9065a inhibits cell proliferation [326], and MCM09 shows
anticancer action by signiﬁcantly lowering lung metastasis
[327].
10.4. FIIa Inhibition. Heparin shows a variety of anti-
inﬂammatory potentials (for review, see [328]). Heparin-
bondedcircuitpreventstheincreasesinIL-6andIL-8inCPB
patients [329], while heparin bolus reduces neutrophil acti-
vation without aﬀecting platelet aggregation [330]. Heparin
is also considered a treatment for pregnancy loss [331].
Direct FIIa inhibitor (hirudin) binds to FIIa active site
and prevents PAR-1 from cleavage [332], thereby dimin-
ishing FIIa signaling in ICAM/VCAM expression [96]a n d
elicitation of VEGF [333, 334], IL-6 [139], IL-8 [93], or
MCP-1 [93]. Hirudin suppresses sTF1-219-induced inﬂam-
mation [80]. A hirudin analog (lepirudin) alleviates LPS-
induced platelet activation [335]. Lepirudin, desirudin, and
bivalirudin [336] exhibit antagonism to DVT, VTE, and
arterial thrombosis in clinical studies.
FIIa active site inhibitor (melagatran) diminishes P-
selectin expression [332], ximelagatran [337] shows various
antithrombotic actions, and argatroban attenuates DVT and
VTE [338]. Org 42675 is a direct anti-FIIa agent with anti-
FXa activity, seemingly being superior to argatroban and
fondaparinux in animal models of thrombosis [339].
A new direct FIIa inhibitor (FM-19) shows platelet
inhibition in vitro and in vivo with an application for
ﬁghting ACS [340]; this oral anticoagulant also inhibits
prostatetumorgrowth invivo [341].SeveralotherdirectFIIa
inhibitors (e.g., argatroban [342], foypan [343], and dabiga-
tranetexilate[344]) show promising anticancerpotentials by
preventingandslowingdowntumorcellmigration,metasta-
sis, and cancer progression. Heparin and dalteparin down-
regulate PAR-1 cleavage [332], blocking PAR-1-mediated
VEGF release in response to FIIa [93]. Heparin also reduces
lung metastasis [327].
10.5. By Natural Anticoagulants: TFPI, APC, or ATIII. TFPI,
a multifunction anticoagulant with trivalent Kunitz-type
domains,downregulatesTF-dependentbloodcoagulationby
inhibiting FXa and TF/FVIIa complex. The ﬁrst domain is
responsible for the inhibition of FVIIa in TF/FVIIa complex
by a feedback inhibition through the inactive quaternary
complex TF/FVIIa/TFPI/FXa, where FXa accelerates TFPI14 International Journal of Inﬂammation
binding to FVIIa. The second domain directly binds and
inhibits FXa. APC directly inactivates FVa and FVIIIa.
FVa is an essential cofactor for FXa (prothrombinase) in
prothrombin activation, while FVIIIa functions as a high-
aﬃnity receptor/cofactor for FIXa (intrinsic Xase) in FX
activation. AT III virtually inhibits all clotting factors at a
slow rate; it mainly targets FIIa, FXa and FIXa. In addition,
AT III complex with FVIIa inactivates FVIIa activity; the
inhibition is enhanced in the presence of TF or heparin.
10.5.1. Anti-Inﬂammatory Actions. TFPI plays a signiﬁcant
role in protecting against septic shock induced by E. coli
in animal models [345], suppressing TNF-α expression
and IL-6 and -8 production. TFPI suppresses coagulation-
dependent IL-8 production [346] or VCAM-1 expression
[347]. In cell cultures, TFPI reduces the autocrine release
of PDGF-BB, MCP-1 and MMP-2 in response to FVIIa,
and FXa [348]. Its coagulation-independent action includes
the direct suppression in TNF-α, IL-6, and IL-8 production
[349], reducing mortality from E. coli septic shock in
baboons. TFPI also directly interferes with LPS reception
[345]. TFPI in place of antibiotics could be a treatment for
pneumonia [350]. Gene therapy with rTFPI could attenuate
pulmonary ﬁbrosis [351]. TFPI could also be used to relieve
rheumatoid arthritis (RA) synovial inﬂammation [261].
It has long been established that APC protects from
sepsis, DIC, and endotoxemia [352, 353]; APC is recognized
as one of the eﬀective anti-inﬂammatory agents in clinical
applications. APC inactivates the production of IL-1, -6, -8
or TNF-α [354]. APC consistently reduces septic mortality
and blocks DIC upon E. coli. infection in either animal or
human models [355, 356].
ATIII blocks FXa-induced IL-6, IL-8, MCP-1,
ICAM/VCAM, and E-selectin expressions [90] in addition
to arresting FIIa-induced (PAR-1-dependent) VEGF release
[93] and MCP-1 expression [89]. ATIII inhibits LPS-
induced IL-6 production [138]. Apart from inactivating
NFκB[ 357], AT III direct anti-inﬂammatory action
includes the suppression in INF-γ and ILs (e.g., 1, 2, 4, 6,
and 8) production, which is mediated by enhanced PGI
production and diminished inducible NOS [358]. However,
a discrepancy exists concerning improved survival rate in
baboons [359] but not severe human sepsis treated with the
high dose of ATIII [360]. Further research warrants verifying
its anti-inﬂammatory action(s).
10.5.2. Antithrombotic Actions. rTFPI exhibits antithrom-
botic eﬀect in a human ex vivo thrombotic model [361]
without protection from dealth though, while a truncated
TFPI 1-161 reduces thrombus formation [362].
APC antithrombotic potential is implied by increased
APC resistance [363] and the deﬁciency [364]o rl o w
plasma level [365] of APC observed in thrombosis. APC
proﬁbrinolytic eﬀects by inactivation of PAI-1 [366]a n d
TAFI [367] synergistically diminish the direct thrombotic
inputs from blood coagulation cascade. However, APC
antithrombotic potential remains in the experimental stage
of animal studies. For instance, a recombinant human APC
(LY203638) inhibits arterial thrombosis in a canine model
[368]. A human APC product (CTC-111) reduces venous
thrombosis in mice [369]. FLIN-Q3 diminishes A-V shunt-
induced thrombosis in guinea pigs [370]. hAPC attenuates
rat mesenteric occlusion [371], and rhAPC inhibits arterial
thrombosis in baboons [372]. Infusion of bovine APC
suppresses thrombus formation in rats [373] and rabbit
microarterial thrombosis [374]. A rabbit APC-loaded stent
reduces thrombus and platelet deposition in vitro and in vivo
[375].
Little is known about the antithrombotic applica-
tion of AT III; a bolus infusion with ATIII attenu-
ates FIIa-induced leukocyte rolling/adhesion/recruitment in
ischemia/reperfusion [376].
10.5.3. Anticancer Properties. The eﬀects of TFPI, a “tumor
suppressor-like molecule,” include enhanced apoptosis [377]
and blocked tumor growth and angiogenesis [288]. TFPI-
2 expression in tumor tissue could inhibit invasion,
tumor growth, and metastasis [378]. ATIII demonstrates
antimetastatic [379] and antiangiogenic potentials [380].
It remains unclear whether APC could exhibit consistent
anticancer beneﬁts [381] regardless of limited evidence
showing inhibited tumor metastasis [382].
10.6.PARAntagonism. PARstransmittingbloodcoagulation
signals to cellular activation for proinﬂammation (Figure 2)
are apparent therapeutical targets for interrupting the cir-
cuit (Figure 3). A growing list of PAR antagonists readily
shows clinical applications concerning inﬂammation and
thrombosis. For instance, RWJ 58259 [383] selectively blocks
PAR-1, resulting in the attenuation in CD61 expression,
platelet aggregation, thrombus formation, and restenosis.
RWJ-56110 protects from FIIa-induced human platelet
activation and platelet-mediated thrombosis [384]. Simi-
larly, PAR-1 antagonists (SCH 79797 and 203099) depress
P-selectin expression and platelet aggregation [385]a n d
VEGF release [386]. SCH 79797 also limits myocardial
ischemia/reperfusion injury in rat hearts [387]a n do ﬀsets
plasmin-induced IL-8 expression and PGE2 release [388].
Orally active himbacine-based SCH 530348 shows potent
antiplatelet activity [389]. Reﬂudan suppresses macrophage
adhesion [390]. BMS 197525 [391] and 200261 [392] abolish
platelet aggregation. Nonpeptide FR 171113 preferentially
diminishes FIIa-induced thrombosis in guinea pig mod-
els [393]. TH146 and MAP4-TH146 readily inhibit FIIa-
induced human platelet aggregation and mouse thrombosis
[394].
By blocking PAR-2 activation, peptide antagonists
(FSLLRY-NH2 and LSIGRL-NH2) suppress Serratia
marcescens serralysin-induced IL-6/8 expression [109].
PAR2 mAb (SAM-11) and PAR2 antagonist (ENMD-1068)
[110] signiﬁcantly attenuate IL-1β production and joint
inﬂammation. Anti-PAR-2 Abs and tryptase inhibitors
(GW-45 and GW-61) cause signiﬁcant decreases in IL-6 and
IL-8 release from human peripheral blood eosinophils [108].
SR 48968 and 140333 reduce contractile [107]. FUT-175
consistent with PAR deﬁciency eases inﬂammatory bowel
disease/symptom [395].International Journal of Inﬂammation 15
PAR4 antagonist (P4pal-10) is used for treatment of
thrombocytopenia and DIC [396] protecting from systemic
inﬂammation accompanied by stabilized liver, kidney, and
lung function. A nonpeptide PAR-4 antagonist (YD-3)
selectively depresses GYPGKF-induced platelet aggregation
[397]. tc-Y-NH(2) and P4pal10 [398] provide protection
against injury from myocardial reperfusion injury. P4pal-10
also protects from platelet-mediated thrombosis [399].
Similarly,generalPARdownregulationcouldalsoachieve
such anti-inﬂammatory and antithrombotic eﬀects. For
instance, IL-4 suppresses PAR-1, -2, and -3 mRNA expres-
sions[400].CathepsinGandneutrophilelastasefacilitatethe
internalizationofPAR-1[401]/-2[402]todesensitize/disarm
the reception function. The ubiquitination of PAR-2 by
β-arrestin attenuates PAR-2 signaling induced by trypsins,
tryptase, and coagulation mediators (FVIIa and FXa) [403].
By increasing GTPase activity of Gq?, NO donors and cGMP
[404]terminatePAR-1signalingandexhibitvascularsmooth
muscle relaxation.
Concerning anticancer potentials, recent research
advances reveal that PARs play roles in cancer metastasis
[405] and angiogenesis [406]. Consistently, reduction
of PAR-1 expression by siRNA or PAR-1 antagonism
by SCH79797 signiﬁcantly suppresses melanoma cell
motility/invasion [406]. SCH79797 suppresses HIF and
Twist expression attenuating cancer metastasis [407], while
blocked VEGF release could be of antiangiogenesis [407].
10.7. Miscellaneous. Downregulation of TF function shows
antithrombotic eﬀects. An i.v. delivered antibody against
rabbitTF(AP-1)inhibitsintravascularthrombosis[408]and
thrombus propagation without aﬀecting bleeding time in
rabbits[409]. Anti-TF mAb is of antisepsis [83]a n dp r ev e n t s
APS-mediated pregnancy loss [234]. TF blocking antibody
(CNTO 859) readily reduces EGFR-mediated tumor ini-
tiation [178] and cancer initiation/angiogenesis [410]. TF
blocking antibody also reduces allograft rejection [411]. Oral
warfarin signiﬁcantly reduces IL-6 at day 15 [412, 413];
this general anticoagulant also shows antagonisms against
tumor growth/metastasis [414]. n-3 FA [25, 415], known
as inﬂammation resolution, oﬀsets AA stimulatory eﬀect
on TF expression [25] to ease inﬂammation and provide
cardioprotection.
11. Remarks
Blood coagulation, a primitive biological phenomenon in
the animal kingdom, has historically been recognized as
a host defense to prevent one from bleeding to death.
TF-initiated extrinsic pathway, known as being inducible
compared to constitutive intrinsic pathway, plays an integral
role in blood coagulation, FIIa generation, and thrombus
formation (for review, see [3, 10, 67]). Accumulating evi-
dence demonstrates TF diverse biological eﬀects in local
or systemic inﬂammation [4]. Not only does the extrinsic
pathway but also intrinsic pathway results in inﬂamma-
tion [416]. Interestingly, TF hypercoagulability refuels a
coagulation-inﬂammation-thrombosis circuit in “autocrine”
or “paracrine” fashion (Figure 3), thereby manifesting many
pathological conditions.
Such extracellular TF signaling activates cells, and its
pronounced eﬀects include proinﬂammatory cytokine pro-
duction (Figure 2). It has been elucidated that inﬂammaso-
mal activation [417] in response to innate pathogens [418],
viral [419], fungus [420], inﬂuenza [421], microbes [422],
and chemicals (e.g., cholesterol [423], uric acid [424], or
aluminium hydroxide [417] crystals, asbestos [425], silica
[425]) is essential for cytokine secretion (for review, see
[426]). It, however, remains elusive if inﬂammasomal activa-
tionisinvolvedinsuchinﬂammatoryprocesstriggeredbyTF
signaling. Thus far, there is no indication whether coagulant
mediators (e.g., FVIIa, FXa, FIIa) could activate procaspase-
1, facilitating proinﬂammatory cytokine secretion. Could
PAR activation directly turn on inﬂammasomal activation,
an interesting question seemingly further addressing the
similar issues if inﬂammasomal activation is critical for
coagulation-dependent inﬂammation?
Among diverse clinical conditions associated with TF
overexpression and its signaling mentioned herein, the
close link between TF hypercoagulability and neurological
disorders is however seldom reported. Although high TF
expression in the brain could in part account for thrombotic
stroke consequences, it certainly warrants investigation to
explore if TF and its signaling participate in other neuronal
dysfunctions or CNS disorders. It would also be of particular
interest to determine the biological events of coagulation
concerningnotonlyinnate[248]butalsoadaptiveimmunity
of B/T cell equipped and featured with such “autocrine” or
“paracrine” TF signaling, if any.
In view of the paradigm of coagulation-inﬂammation-
thrombosis circuit eliciting diverse pathological events
(Figure 3), targeting TF hypercoagulation is of therapeutical
relevance. Apparently, the development of anticoagulants
is of broad pharmaceutical interests; anticoagulation could
turn into strategic approaches for intervention and cure
not limiting to thromboprophylaxis. It is highly promising
that anticoagulants available arresting diﬀerent stages of
blood coagulation cascade [427] exhibit beneﬁts other
than hemostasis. Approaches to direct FVIIa, FXa, or FIIa
inhibition readily demonstrate broad clinical applications
(Table 1). In these regards, TF posttranslational down-
regulation (including encryption) could deserve attention
for interventional therapeutical relevance in prospective of
such upstream downregulation of the extrinsic pathway
(Figure 2, left panel) with broad suppression of downstream
proinﬂammatory coagulant mediators (e.g., FVIIa, FXa, and
F I I a )a sw e l la sﬁ b r i np r o d u c t i o n .
The observations of anticoagulation exhibiting anti-
cancer properties clearly demonstrate the new frontiers of
the emerging therapeutical era. Direct PAR blockade could
be part of therapeutically targeting coagulation-dependent
inﬂammation and the circuit (Figure 3). Further research is
needed to study if PAR antagonisms could widely exhibit
an array of clinical beneﬁts to relieve diseases including
cancer, obesity, diabetes, APS, and others in addition to
inﬂammationandthromboticrelatedcardiovascularcompli-
cations.16 International Journal of Inﬂammation
Like any other therapies, anticoagulation bears certain
limitations and cautions for its applications. For employing
anticoagulants, bleeding or hemorrhage episodes become
major concerns in relation to the safety and eﬃcacy issues
upon long-term uses or “over dosages.” With cautions
in mind, routine monitoring for hemostatic properties
is highly recommended. Further investigations warrant
addressing rationally designed anticoagulant approaches to
achieving/maintaining/weighing in therapeutical beneﬁts for
diverse clinical applications.
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FIIa: Thrombin
FVIIa: Activated factor VII
FVIIai: Active site inhibited FVIIa
FXa: Activated factor X
HMGCR: HMGCoA reductase
ICAM: Intracellular adhesion molecule
IL: Interleukin
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